At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Albuterol +1 moredrug
Likely dose
Albuterol 270μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Inhaled Albuterol on Pulmonary Hemodynamics in Patients With Group 1 Pulmonary Arterial Hypertension on Oral Pulmonary Vasodilator Therapy: A Proof of Concept Study
In Brief
A Phase 2 clinical trial evaluating Albuterol and Placebo for Pulmonary Hypertension. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of the present pilot study is to test the hypothesis that in patients with group 1 pulmonary arterial hypertension (PAH) who are on regular oral pulmonary vasodilator therapy, inhaled albuterol causes transient pulmonary vasodilation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartOct 2017
Primary CompletionJul 2020
TodayJul 2026
First PostedSep 1, 2017
Enrollment StartOct 5, 2017
Primary CompletionJul 2, 2020
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 8.8 years ago
Interventions
Albuteroldrug
inhalation of 270μg albuterol through a spacer
Placebodrug
inhalation of placebo through a spacer